CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 84 enrolled
Drug / intervention
Tranexamic Aciddrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02584725
NCT02584725Phase 4Completed
CompareCT.gov

Determining the Optimal Dose of Tranexamic Acid in Decreasing Blood Loss During Lower Extremity Total Joint Arthroplasty

Columbia University·interventional·Posted Oct 23, 2015·Updated Oct 30, 2020

In Brief

A Phase 4 clinical trial evaluating Tranexamic Acid for Arthropathy of Hip and Arthropathy of Knee. Completed, enrolled 84 participants.

Detailed Summary

The purpose of this study is to determine the effect of increasing doses of tranexamic acid (TXA) on limiting blood loss during total knee and total hip arthroplasty as defined by a change in hemoglobin from pre-operative baseline to the first post-operative day.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArthropathy of Hip, Arthropathy of Knee
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 23, 2015
Enrollment StartDec 1, 2014
Primary CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 10.7 years ago

Interventions

Tranexamic Aciddrug

Comparison of 3 different doses of the drug